Eli Levine, MD
Interventional Cardiology · Boca Raton, FLNPI 1457526311
Payments from drug & device makers
Across 307 payments — averaging $39.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Boston Scientific$2K
- Bard Peripheral Vascular, Inc.$883
- Cardiovascular Systems Inc.$827
- Medtronic$644
- Cook Medical LLC$612
- plus $4K from 30 others
What the payments were for
- Travel & lodging$3823%
- Food & beverage$11,50096%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 53 | $3,192 |
| Boston Scientific | 47 | $1,947 |
| Bard Peripheral Vascular, Inc. | 31 | $883 |
| Cardiovascular Systems Inc. | 10 | $827 |
| Medtronic(2 entities) | 16 | $644 |
| Cook Medical LLC | 14 | $612 |
| Pfizer | 14 | $338 |
| Biotronik Inc. | 9 | $323 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $317 |
| Atricure, Inc. | 6 | $308 |
| Amarin Pharma, Inc. | 15 | $307 |
| Johnson & Johnson | 11 | $304 |
| Shockwave Medical, Inc | 6 | $286 |
| Abiomed | 2 | $268 |
| Novartis | 12 | $218 |
| Edwards Lifesciences | 2 | $155 |
| AstraZeneca | 6 | $154 |
| Heartflow, Inc. | 1 | $145 |
| Boehringer Ingelheim | 3 | $137 |
| Amgen | 4 | $85 |
| Cvrx, Inc. | 4 | $82 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Kestra Medical Technology Services, Inc. | 2 | $57 |
| Cleerly, Inc. | 2 | $46 |
| Penumbra, Inc. | 2 | $42 |
| Philips North America LLC | 1 | $36 |
| Acutus Medical, Inc. | 2 | $32 |
| Merck | 2 | $30 |
| Tactile Systems Technology Inc | 1 | $23 |
| BD | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $18 |
| Vital Connect, Inc | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Smith+Nephew | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$570
- LUX-Dx Insertable Cardiac Monitor$535
- Coronary Orbital Atherectomy System$514
- Confirm Rx$382
- JOT DX$309
- Impella$268
- ENSITE$241
- BodyGuardian$238
- MitraClip$196
- ClosureFast$195
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$187
- SYNERGY ABLATION SYSTEM$183
- AMPLATZER AMULET$180
- Optis Coronary Imaging System$164
- EMBLEM MRI S-ICD$158
- MITRIS RESILIA Mitral Valve$145
- FFRct$145
- VenaSeal$140
- Zilver PTX$130
- XARELTO$129
How this compares
$11,996 in reported general payments places this provider in the 55th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 335 | $403,587 |
| EntrestoSacubitril/Valsartan | 103 | $152,568 |
| FarxigaDapagliflozin Propanediol | 108 | $131,555 |
| Repatha SureclickEvolocumab | 99 | $81,666 |
| XareltoRivaroxaban | 47 | $66,619 |
| JardianceEmpagliflozin | 50 | $54,939 |
| BrilintaTicagrelor | 32 | $28,961 |
| Praluent PenAlirocumab | 25 | $15,566 |
| MounjaroTirzepatide | 14 | $13,140 |
| Metoprolol Succinate | 586 | $10,515 |
| Bumetanide | 319 | $9,864 |
| Potassium Chloride | 227 | $5,312 |
| Rosuvastatin Calcium | 398 | $4,842 |
| Losartan Potassium | 323 | $3,162 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 162 | $2,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $338 | $403,587335 claims |
| AstraZenecaFarxiga, Brilinta | $154 | $160,516140 claims |
| NovartisEntresto | $218 | $152,568103 claims |
| Johnson & JohnsonXarelto | $304 | $66,61947 claims |
| Boehringer IngelheimJardiance | $137 | $54,93950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Boca Raton
- Michael CammarataBoca Raton$685K
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.